biphasic insulin aspart — Competitive Intelligence Brief

biphasic insulin aspart (biphasic insulin aspart) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin analog (biphasic). Area: Diabetes.

marketed Insulin analog (biphasic) Insulin receptor Diabetes Small molecule

Target snapshot

biphasic insulin aspart (biphasic insulin aspart) — Novo Nordisk A/S. Biphasic insulin aspart is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in cells, with a biphasic formulation providing both immediate and intermediate insulin coverage.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
biphasic insulin aspart TARGET	biphasic insulin aspart	Novo Nordisk A/S	marketed	Insulin analog (biphasic)	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin analog (biphasic) class)

1. Medical University of Graz · 1 drug in this class
2. Novo Nordisk A/S · 1 drug in this class